Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine

Yasutaka Kato, Hiroshi Nishihara, Sayaka Yuzawa, Hiromi Mohri, Hiromi Kanno, Yutaka Hatanaka, Taichi Kimura, Mishie Tanino, Shinya Tanaka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Recent progress in molecule-targeting therapy may yield personalized therapeutic strategies for patients with metastatic brain tumors (MBT), the most frequently encountered intracranial tumors. For this purpose, we investigated the molecular expression profile of MBT to establish the pathological basis for personalized diagnosis. We studied 166 MBT specimens including 70 cases of lung cancer and 34 cases of breast cancer, and performed immunostaining for EGFR, COX-2, and O-6-methylguanine-DNA methyltransferase (MGMT), among others, which could be target molecules for therapeutic agents or enable prediction of drug efficacy. Loss of MGMT expression was observed in approximately 20-40 % of MBT derived from lung, breast, and gastrointestinal cancers, indicating the possibility of treatment of MBT patients with temozolomide. In addition, MBT expressed a variety of receptor tyrosine kinases, for example EGFR and HER2, and signal transduction molecules, for example phospho-mTOR and COX-2, irrespective of tumor origin, enabling individualized medication with molecule-targeting drugs. We also identified alteration of molecular expression profile in 4 MBT cases during recurrence. Our results not only reveal the molecular characteristics of MBT but also suggest the possibility of potent personalized medicine for MBT patients.

Original languageEnglish
Pages (from-to)167-174
Number of pages8
JournalBrain tumor pathology
Volume30
Issue number3
DOIs
Publication statusPublished - 2013 Jan 1
Externally publishedYes

Fingerprint

Precision Medicine
Brain Neoplasms
O(6)-Methylguanine-DNA Methyltransferase
temozolomide
Lung Neoplasms
Breast Neoplasms
Gastrointestinal Neoplasms
Receptor Protein-Tyrosine Kinases
Therapeutics
Drug Delivery Systems
Signal Transduction
Neoplasms
Recurrence

Keywords

  • Immunohistochemistry
  • Metastatic brain tumor
  • Molecular expression profile
  • Personalized medicine

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine. / Kato, Yasutaka; Nishihara, Hiroshi; Yuzawa, Sayaka; Mohri, Hiromi; Kanno, Hiromi; Hatanaka, Yutaka; Kimura, Taichi; Tanino, Mishie; Tanaka, Shinya.

In: Brain tumor pathology, Vol. 30, No. 3, 01.01.2013, p. 167-174.

Research output: Contribution to journalArticle

Kato, Y, Nishihara, H, Yuzawa, S, Mohri, H, Kanno, H, Hatanaka, Y, Kimura, T, Tanino, M & Tanaka, S 2013, 'Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine', Brain tumor pathology, vol. 30, no. 3, pp. 167-174. https://doi.org/10.1007/s10014-012-0124-y
Kato, Yasutaka ; Nishihara, Hiroshi ; Yuzawa, Sayaka ; Mohri, Hiromi ; Kanno, Hiromi ; Hatanaka, Yutaka ; Kimura, Taichi ; Tanino, Mishie ; Tanaka, Shinya. / Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine. In: Brain tumor pathology. 2013 ; Vol. 30, No. 3. pp. 167-174.
@article{0e5ecfad00984cf6ab8b7f44b1f900c6,
title = "Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine",
abstract = "Recent progress in molecule-targeting therapy may yield personalized therapeutic strategies for patients with metastatic brain tumors (MBT), the most frequently encountered intracranial tumors. For this purpose, we investigated the molecular expression profile of MBT to establish the pathological basis for personalized diagnosis. We studied 166 MBT specimens including 70 cases of lung cancer and 34 cases of breast cancer, and performed immunostaining for EGFR, COX-2, and O-6-methylguanine-DNA methyltransferase (MGMT), among others, which could be target molecules for therapeutic agents or enable prediction of drug efficacy. Loss of MGMT expression was observed in approximately 20-40 {\%} of MBT derived from lung, breast, and gastrointestinal cancers, indicating the possibility of treatment of MBT patients with temozolomide. In addition, MBT expressed a variety of receptor tyrosine kinases, for example EGFR and HER2, and signal transduction molecules, for example phospho-mTOR and COX-2, irrespective of tumor origin, enabling individualized medication with molecule-targeting drugs. We also identified alteration of molecular expression profile in 4 MBT cases during recurrence. Our results not only reveal the molecular characteristics of MBT but also suggest the possibility of potent personalized medicine for MBT patients.",
keywords = "Immunohistochemistry, Metastatic brain tumor, Molecular expression profile, Personalized medicine",
author = "Yasutaka Kato and Hiroshi Nishihara and Sayaka Yuzawa and Hiromi Mohri and Hiromi Kanno and Yutaka Hatanaka and Taichi Kimura and Mishie Tanino and Shinya Tanaka",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/s10014-012-0124-y",
language = "English",
volume = "30",
pages = "167--174",
journal = "Brain Tumor Pathology",
issn = "1433-7398",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine

AU - Kato, Yasutaka

AU - Nishihara, Hiroshi

AU - Yuzawa, Sayaka

AU - Mohri, Hiromi

AU - Kanno, Hiromi

AU - Hatanaka, Yutaka

AU - Kimura, Taichi

AU - Tanino, Mishie

AU - Tanaka, Shinya

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Recent progress in molecule-targeting therapy may yield personalized therapeutic strategies for patients with metastatic brain tumors (MBT), the most frequently encountered intracranial tumors. For this purpose, we investigated the molecular expression profile of MBT to establish the pathological basis for personalized diagnosis. We studied 166 MBT specimens including 70 cases of lung cancer and 34 cases of breast cancer, and performed immunostaining for EGFR, COX-2, and O-6-methylguanine-DNA methyltransferase (MGMT), among others, which could be target molecules for therapeutic agents or enable prediction of drug efficacy. Loss of MGMT expression was observed in approximately 20-40 % of MBT derived from lung, breast, and gastrointestinal cancers, indicating the possibility of treatment of MBT patients with temozolomide. In addition, MBT expressed a variety of receptor tyrosine kinases, for example EGFR and HER2, and signal transduction molecules, for example phospho-mTOR and COX-2, irrespective of tumor origin, enabling individualized medication with molecule-targeting drugs. We also identified alteration of molecular expression profile in 4 MBT cases during recurrence. Our results not only reveal the molecular characteristics of MBT but also suggest the possibility of potent personalized medicine for MBT patients.

AB - Recent progress in molecule-targeting therapy may yield personalized therapeutic strategies for patients with metastatic brain tumors (MBT), the most frequently encountered intracranial tumors. For this purpose, we investigated the molecular expression profile of MBT to establish the pathological basis for personalized diagnosis. We studied 166 MBT specimens including 70 cases of lung cancer and 34 cases of breast cancer, and performed immunostaining for EGFR, COX-2, and O-6-methylguanine-DNA methyltransferase (MGMT), among others, which could be target molecules for therapeutic agents or enable prediction of drug efficacy. Loss of MGMT expression was observed in approximately 20-40 % of MBT derived from lung, breast, and gastrointestinal cancers, indicating the possibility of treatment of MBT patients with temozolomide. In addition, MBT expressed a variety of receptor tyrosine kinases, for example EGFR and HER2, and signal transduction molecules, for example phospho-mTOR and COX-2, irrespective of tumor origin, enabling individualized medication with molecule-targeting drugs. We also identified alteration of molecular expression profile in 4 MBT cases during recurrence. Our results not only reveal the molecular characteristics of MBT but also suggest the possibility of potent personalized medicine for MBT patients.

KW - Immunohistochemistry

KW - Metastatic brain tumor

KW - Molecular expression profile

KW - Personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=84880784577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880784577&partnerID=8YFLogxK

U2 - 10.1007/s10014-012-0124-y

DO - 10.1007/s10014-012-0124-y

M3 - Article

C2 - 23180004

AN - SCOPUS:84880784577

VL - 30

SP - 167

EP - 174

JO - Brain Tumor Pathology

JF - Brain Tumor Pathology

SN - 1433-7398

IS - 3

ER -